YH29407 / Yuhan Corp - LARVOL DELTA

"K-Bio shows off new cancer-conquering technology"… American Cancer Society's 'AACR' scramble [Google translation] (Nate) - "Yuhan Corporation announces the results of pre-clinical studies on YH32367 (ABL105) and 'YH29407', which are being developed as immuno-oncology drugs. YH32367, a drug under joint research with ABL Bio, is an anticancer drug that binds to HER2-expressing tumor cells and increases the anticancer activity of immune cells through stimulation of 4-1BB, a T immune cell activation receptor."

Preclinical • Oncology

YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment. (PubMed, Front Chem) - "In this study, we compared the anti-tumor effects of YH29407, the best-in-class IDO1 inhibitor with improved pharmacodynamics and pharmacokinetics, with first and second-generation IDO1 inhibitors (epacadostat and BMS-986205, respectively). Our results suggest that an IDO1 inhibitor, YH29407, has enhanced PK/PD compared to previous IDO1 inhibitors by causing a change in the population of CD8 T cells including infiltrating T cells into the tumor. Ultimately, YH29407 overcame the limitations of the competing drugs and displayed potential as an immunotherapy strategy in combination with aPD-1."

Biomarker • IO biomarker • Journal • Tumor microenvironment • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • B2M • CD8 • LCK • MYD88 • ZAP70

Combination therapy with anti-PD-1 and YH29407, a novel IDO1 inhibitor, enhances T cell-mediated antitumor immunity in MC38 tumor-bearing mice (AACR 2022) - "Taken together, we suggest that YH29407 is the best combination partner with immune checkpoint inhibitors for solid tumor."

Combination therapy • Preclinical • Oncology • Solid Tumor • CD8

[VIRTUAL] YH29407, a novel IDO1 inhibitor, enhances the anti-tumor effects through increased tumor-reactive T cell functions in solid tumor (AACR 2021) - "The novel IDO1 inhibitor, YH29407, with improved pharmacokinetic and pharmacodynamic profiles, showed antitumor inflammatory reprogramming leading to enhanced antitumor efficacy."

IO biomarker • Oncology • Solid Tumor • FASLG • GZMB • IFNG • IL12A • MMP2